JP7460639B2 - 血液癌を治療するための併用療法 - Google Patents

血液癌を治療するための併用療法 Download PDF

Info

Publication number
JP7460639B2
JP7460639B2 JP2021539498A JP2021539498A JP7460639B2 JP 7460639 B2 JP7460639 B2 JP 7460639B2 JP 2021539498 A JP2021539498 A JP 2021539498A JP 2021539498 A JP2021539498 A JP 2021539498A JP 7460639 B2 JP7460639 B2 JP 7460639B2
Authority
JP
Japan
Prior art keywords
pyridin
axl
pyrazol
bcl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021539498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501434A (ja
JP2022501434A5 (enExample
Inventor
ザイホイ・ジャン
シャオヤン・ジアン
カタリーナ・ローテ
シャオジア・ニウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signalchem Lifesciences Corp
Original Assignee
Signalchem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signalchem Lifesciences Corp filed Critical Signalchem Lifesciences Corp
Publication of JP2022501434A publication Critical patent/JP2022501434A/ja
Publication of JP2022501434A5 publication Critical patent/JP2022501434A5/ja
Application granted granted Critical
Publication of JP7460639B2 publication Critical patent/JP7460639B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021539498A 2018-09-18 2019-09-18 血液癌を治療するための併用療法 Active JP7460639B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732816P 2018-09-18 2018-09-18
US62/732,816 2018-09-18
PCT/US2019/051764 WO2020061216A1 (en) 2018-09-18 2019-09-18 Combination therapy for treating blood cancer

Publications (3)

Publication Number Publication Date
JP2022501434A JP2022501434A (ja) 2022-01-06
JP2022501434A5 JP2022501434A5 (enExample) 2022-09-28
JP7460639B2 true JP7460639B2 (ja) 2024-04-02

Family

ID=68104787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539498A Active JP7460639B2 (ja) 2018-09-18 2019-09-18 血液癌を治療するための併用療法

Country Status (13)

Country Link
US (1) US12097194B2 (enExample)
EP (1) EP3852766B1 (enExample)
JP (1) JP7460639B2 (enExample)
KR (1) KR102764125B1 (enExample)
CN (1) CN112739349B (enExample)
AU (1) AU2019343044B2 (enExample)
BR (1) BR112021005054A2 (enExample)
CA (1) CA3110901C (enExample)
IL (1) IL281439B2 (enExample)
MX (1) MX2021003062A (enExample)
SG (1) SG11202101955SA (enExample)
TW (1) TWI824010B (enExample)
WO (1) WO2020061216A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
EP4054585A1 (en) 2019-11-05 2022-09-14 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof
TW202545523A (zh) * 2024-02-05 2025-12-01 加拿大商聖諾康生命科學公司 用於治療血液癌症之組合療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540577A (ja) 2005-05-12 2008-11-20 アボット・ラボラトリーズ アポトーシス促進剤
JP2017501981A (ja) 2013-11-27 2017-01-19 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
BRPI1007046B1 (pt) 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
RU2593231C2 (ru) 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
US9993472B2 (en) * 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008540577A (ja) 2005-05-12 2008-11-20 アボット・ラボラトリーズ アポトーシス促進剤
JP2017501981A (ja) 2013-11-27 2017-01-19 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia，Cancer Discovery，2014年，Vol.4, No.3，p.362-375

Also Published As

Publication number Publication date
US20220031685A1 (en) 2022-02-03
WO2020061216A1 (en) 2020-03-26
CA3110901C (en) 2024-01-02
IL281439A (en) 2021-04-29
KR102764125B1 (ko) 2025-02-07
IL281439B1 (en) 2024-10-01
IL281439B2 (en) 2025-02-01
US12097194B2 (en) 2024-09-24
AU2019343044B2 (en) 2025-03-06
SG11202101955SA (en) 2021-03-30
EP3852766B1 (en) 2024-05-08
JP2022501434A (ja) 2022-01-06
EP3852766A1 (en) 2021-07-28
CA3110901A1 (en) 2020-03-26
TW202023554A (zh) 2020-07-01
TWI824010B (zh) 2023-12-01
BR112021005054A2 (pt) 2021-06-08
MX2021003062A (es) 2021-05-27
AU2019343044A1 (en) 2021-03-18
CN112739349A (zh) 2021-04-30
KR20210061356A (ko) 2021-05-27
CN112739349B (zh) 2024-03-01

Similar Documents

Publication Publication Date Title
KR102764125B1 (ko) 혈액암 치료를 위한 조합요법
JP7476380B2 (ja) 血液学的障害を治療するための化合物および組成物
JP2023520333A (ja) Ｅｉｆ４ａ阻害剤組み合わせ
JP6180420B2 (ja) 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
JP2020512343A (ja) 血液疾患を処置するための化合物及び組成物
AU2017220738A1 (en) Carboxamide derivatives useful as RSK inhibitors
BR112021002632A2 (pt) compostos e composições de ureia como inibidores de smarca2/brm atpase
TW201244719A (en) Combinations of kinase inhibitors for the treatment of cancer
TW202031253A (zh) 治療黑色素瘤的藥物組合
EP2763998A1 (en) Tri-heterocyclic derivatives, preparation process and uses thereof
KR20220101656A (ko) 병용 의약
CA2608171C (en) Use of quinolinone compounds for treating drug resistant cancers
US9549921B2 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis C
CN112237579A (zh) 药物组合及其用途
HK40042345A (en) Combination therapy for treating blood cancer
HK40042345B (en) Combination therapy for treating blood cancer
CN116546986A (zh) Alk-5抑制剂及其用途
JP2026507092A (ja) 健康状態の治療のための小分子を作製および使用するための組成物および方法
HK40035225A (en) Pharmaceutical combination and use thereof
HK1110477B (en) Methods for treating drug resistant cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240321

R150 Certificate of patent or registration of utility model

Ref document number: 7460639

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150